Immatics (IMTX) Shares Outstanding (Weighted Average) (2019 - 2025)
Immatics recorded quarterly Shares Outstanding (Weighted Average) of $156.1 million in Q4 2025, up 10978245.92% quarter-over-quarter from $1421.6 in Q3 2025, and up 20.15% year-over-year from $129.9 million in Q4 2024.
Immatics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $156.1 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 20.15% year-over-year to $156.1 million; the TTM figure through Dec 2025 stood at $156.1 million (up 20.15% YoY), while the FY2025 annual figure was $151.5 million, up 16.62% from the prior year.
- Shares Outstanding (Weighted Average) came in at $156.1 million for Q4 2025 at Immatics, up from $1421.6 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.3 billion in Q1 2025 to a low of $10.86 in Q1 2024.
- A 5-year average of $181.1 million and a median of $70.3 million in 2021 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) sank 100.0% in 2024 and surged 11774083977.95% in 2025, its largest moves.
- Immatics' Shares Outstanding (Weighted Average) stood at $72.0 million in 2021, then slipped by 4.71% to $68.6 million in 2022, then gained by 26.36% to $86.7 million in 2023, then surged by 49.88% to $129.9 million in 2024, then increased by 20.15% to $156.1 million in 2025.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $156.1 million, $1421.6, and $1030.1 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 156.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156.06 Mn |
| Sep 30, 2025 | 1,421.57 |
| Jun 30, 2025 | 1,030.08 |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 129.89 Mn |
| Sep 30, 2024 | 43.93 |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 10.86 |
| Dec 31, 2023 | 86.66 Mn |
| Sep 30, 2023 | 90.77 Mn |
| Jun 30, 2023 | 631,576.15 |
| Mar 31, 2023 | 823.25 Mn |
| Dec 31, 2022 | 68.58 Mn |
| Sep 30, 2022 | 66.18 Mn |
| Jun 30, 2022 | 696.79 Mn |
| Mar 31, 2022 | 1,526.38 |
| Dec 31, 2021 | 71.97 Mn |
| Sep 30, 2021 | 74.19 Mn |
| Jun 30, 2021 | 939.33 |
| Mar 31, 2021 | 75.88 Mn |
| Dec 31, 2020 | 57.23 Mn |
| Sep 30, 2020 | 73.48 Mn |
| Jun 30, 2020 | 980,299.52 |
| Mar 31, 2020 | 36.53 Mn |
| Dec 31, 2019 | 36.63 Mn |
| Sep 30, 2019 | 36.82 Mn |
| Jun 30, 2019 | 1.31 Bn |